Publikationer av Hanna Tegel
Refereegranskade
Artiklar
[1]
J. Yan et al., "Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease," Molecular Therapy, vol. 32, no. 2, s. 540-555, 2024.
[2]
M. Dannemeyer et al., "Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors," Protein Expression and Purification, vol. 221, 2024.
[3]
R. Rossi et al., "A Proof of Principle Proteomic Study Detects Dystrophin in Human Plasma : Implications in DMD Diagnosis and Clinical Monitoring," International Journal of Molecular Sciences, vol. 24, no. 6, 2023.
[4]
M. Möller et al., "An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries," Protein Engineering Design & Selection, vol. 36, 2023.
[5]
C. Johansson et al., "Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers," Clinical Proteomics, vol. 20, no. 1, 2023.
[6]
C. Johansson et al., "Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers," Clinical Proteomics, vol. 20, no. 1, 2023.
[7]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, s. 46-52, 2022.
[8]
S. Appelberg et al., "A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells," EMBO Molecular Medicine, vol. 14, no. 10, 2022.
[9]
M. Jönsson et al., "CaRA – A multi-purpose phage display library for selection of calcium-regulated affinity proteins," New Biotechnology, vol. 72, s. 159-167, 2022.
[10]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," Metabolic engineering, vol. 72, s. 171-187, 2022.
[11]
M. Bronge et al., "Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis," Science Advances, vol. 8, no. 17, 2022.
[12]
I. Lauren et al., "Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology," Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.
[13]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, s. 72-80, 2022.
[14]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, s. e0262169-e0262169, 2022.
[15]
M. Ding et al., "Secretome screening reveals immunomodulating functions of IFNα-7, PAP and GDF-7 on regulatory T-cells," Scientific Reports, s. 16767, 2021.
[16]
E. von Witting et al., "Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension," Molecular Pharmaceutics, vol. 18, no. 1, s. 328-337, 2021.
[17]
S. Hober et al., "Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay," Clinical & Translational Immunology (CTI), vol. 10, no. 7, 2021.
[18]
S. Meister et al., "An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor," International Journal of Molecular Sciences, vol. 21, no. 8, s. 2999, 2020.
[19]
H. Tegel et al., "High throughput generation of a resource of the human secretome in mammalian cells," New Biotechnology, vol. 58, s. 45-54, 2020.
[20]
S. Kanje et al., "Improvements of a high-throughput protein purification process using a calcium-dependent setup," Protein Expression and Purification, vol. 175, 2020.
[21]
A.-S. Rudberg et al., "SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.," Nature Communications, vol. 11, no. 1, 2020.
[22]
M. Ding et al., "Secretome-Based Screening in Target Discovery," SLAS Discovery, vol. 25, no. 6, s. 535-551, 2020.
[23]
K. Jennbacken et al., "Phenotypic Screen with the Human Secretome Identifies FGF16 as Inducing Proliferation of iPSC-Derived Cardiac Progenitor Cells," International Journal of Molecular Sciences, vol. 20, no. 23, 2019.
[24]
F. Edfors et al., "Screening a Resource of Recombinant Protein Fragments for Targeted Proteomics," Journal of Proteome Research, vol. 18, no. 7, s. 2706-2718, 2019.
[25]
R. S. Häussler et al., "Systematic Development of Sandwich Immunoassays for the Plasma Secretome," Proteomics, 2019.
[26]
[27]
F. Edfors et al., "Enhanced validation of antibodies for research applications," Nature Communications, vol. 9, 2018.
[28]
[29]
A. Sastry et al., "Machine learning in computational biology to accelerate high-throughput protein expression," Bioinformatics, vol. 33, no. 16, s. 2487-2495, 2017.
[30]
M. Lundqvist et al., "Solid-phase cloning for high-throughput assembly of single and multiple DNA parts," Nucleic Acids Research, vol. 43, no. 7, 2015.
[31]
M. Uhlén et al., "Tissue-based map of the human proteome," Science, vol. 347, no. 6220, s. 1260419, 2015.
[32]
L. Fagerberg et al., "Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics," Molecular & Cellular Proteomics, vol. 13, no. 2, s. 397-406, 2014.
[33]
L. Fagerberg et al., "Contribution of antibody-based protein profiling to the human chromosome-centric proteome project (C-HPP)," Journal of Proteome Research, vol. 12, no. 6, s. 2439-2448, 2013.
[34]
H. Tegel, J. Ottosson och S. Hober, "Enhancing the protein production levels in Escherichia coli with a strong promoter," The FEBS Journal, vol. 278, no. 5, s. 729-739, 2011.
[35]
H. Tegel et al., "Parallel production and verification of protein products using a novel high-throughput screening method," Biotechnology Journal, vol. 6, no. 8, s. 1018-1025, 2011.
[36]
H. Tegel et al., "Increased levels of recombinant human proteins with the Escherichia coli strain Rosetta(DE3)," Protein Expression and Purification, vol. 69, no. 2, s. 159-167, 2010.
[37]
A. Neubauer et al., "Controlling nutrient release in cell cultivation," Genetic Engineering and Biotechnology News, vol. 29, no. 11, s. 50-51, 2009.
[38]
H. Tegel et al., "High-throughput protein production--lessons from scaling up from 10 to 288 recombinant proteins per week," Biotechnology Journal, vol. 4, no. 1, s. 51-57, 2009.
[39]
M. Uhlén et al., "A human protein atlas for normal and cancer tissues based on antibody proteomics," Molecular & Cellular Proteomics, vol. 4, no. 12, s. 1920-1932, 2005.
Icke refereegranskade
Artiklar
[40]
M. Bronge et al., "T cell reactivity screening reveals four novel CNS autoantigens in multiple sclerosis," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, s. 344-345, 2021.
[41]
P. Neubauer et al., "EnBase (TM) - MTP based high-cell-density fermentation for high-throughput and high-content screening," New Biotechnology, vol. 25, s. S161-S161, 2009.
[42]
P. Neubauer et al., "Using EnBase (TM) to enhance recombinant protein production," New Biotechnology, vol. 25, s. S190-S190, 2009.
[43]
H. Tegel et al., "Flow cytometry-based analysis of promoter effects on solubility of recombinantly expressed proteins," Journal of Biotechnology, vol. 131, no. 2, s. S9-S9, 2007.
[44]
J. Ottosson et al., "High throughput protein production and purification in the Human Protein Atlas program," Molecular & Cellular Proteomics, vol. 5, no. 10, s. S40-S40, 2006.
[45]
S. Tourle et al., "Increased levels of recombinant human proteins in E-Coli Rosetta that compensates for mammalian codon usage," Molecular & Cellular Proteomics, vol. 5, no. 10, s. S223-S223, 2006.
[46]
J. Ottosson et al., "High throughput antibody generation and validation for antibody proteomics," Molecular & Cellular Proteomics, vol. 4, no. 8, s. S64-S64, 2005.
[47]
H. Tegel et al., "Novel flow cytometry-based method for analysis of protein production in Escherichia coli," Molecular & Cellular Proteomics, vol. 4, no. 8, s. S66-S66, 2005.
[48]
J. Ottosson et al., "High throughput protein expression and purification for antibody proteomics," Molecular & Cellular Proteomics, vol. 3, no. 10, s. S169-S169, 2004.
Avhandlingar
[49]
H. Tegel, "Proteome wide protein production," Doktorsavhandling Stockholm : KTH Royal Institute of Technology, Trita-BIO-Report, 2013:17, 2013.
Övriga
[50]
A. Wisniewski et al., "A novel TNFα binding ADAPT with increased therapeutic efficiency through multimerization," (Manuskript).
[51]
[52]
E. von Witting et al., "ADAPT as a single-domain bispecific scaffold capable of albumin-associated haf-life extension for therapeutic applications," (Manuskript).
[53]
M. Jonsson et al., "CaRA – A Multi-Purpose Phage Display Library for Selection of Calcium-Regulated Affinity Proteins," (Manuskript).
[54]
M. Jönsson et al., "Engineering of calcium-regulated affinity targeting EGFR-expressing cells for efficient internalization," (Manuskript).
[55]
[56]
H. Tegel et al., "In-depth study of the positive effects of Escherichia coli Rosetta(DE3) on recombinant protein production," (Manuskript).
[57]
T. Boström et al., "Investigating the correlation of protein and mRNA levels in human cell lines using quantitative proteomics and transcriptomics," (Manuskript).
[58]
A. Jernbom Falk et al., "Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19," (Manuskript).
[59]
A. Wisniewski et al., "Single domain ADAPT able to target Interleukin-17c with high affinity and albumin simultaneously for potential half-life extension," (Manuskript).
Senaste synkning med DiVA:
2024-06-30 03:14:02